Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Is Abbott's January Pullback a Good Time to Buy? By Thomas Hughes. Published: 1/24/2026. 
Key Takeaways - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making the stock look attractively valued. The move — driven more by market angst than by any material weakness — appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
The former CEO of Google calls it the most important thing to happen in 500, maybe 1,000 years of human society. A former U.S. Treasury Secretary says when your great-grandchildren write the history of this period, the political headlines will be the second or third story. The first story is something none of us have seen before. The dot-com collapse, global financial crisis, and COVID-19 pandemic don't compare to what's coming next. We may be entering a period of dramatic, almost unimaginable change. See the full warning and how to prepare now. The zone in question aligns with market action from 2022–2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutional investors were actively accumulating the stock. Abbott Laboratories Growth Accelerates At worst, Abbott Laboratories' Q4 results and guidance showed a few metrics that missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth missed by several hundred basis points, but margin strength helped offset that shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. Segment results underscored the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition fell nearly 9% — but those declines were largely offset by solid growth in Established Pharmaceuticals and MedTech. The Established Pharmaceuticals segment grew roughly 9%, driven by generics and emerging markets, while MedTech climbed about 12.3%, showing strength across subsegments. Margins improved, though they were slightly below some analyst forecasts. A favorable product mix, strength in MedTech, reduced COVID-19-related sales and operational improvements all supported margin gains. Looking ahead, the company expects earnings to grow about 10% in 2026, outpacing revenue growth and supporting its capital return plan. Capital returns are central to the buying case. Abbott is a Dividend King, having raised its dividend for more than 50 consecutive years, and it appears positioned to continue doing so. After the pullback the stock yields roughly 2.5%, and the company's payout ratio is below 50% of consensus EPS estimates, leaving room for share buybacks — a key offset to dilutive share-based compensation — alongside the dividend. Share repurchases remain an important component of total shareholder return. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts flagged the revenue miss, but no major rating or price-target changes were issued the morning of the release. The prevailing view is that this fundamentally healthy company can continue returning capital while reinvesting for growth. The consensus price target reported by MarketBeat implies as much as ~30% upside — potentially reaching new highs — while even the low-end target suggests some upside potential. Key catalysts include an expanding MedTech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The acquisition of Exact Sciences, for example, would broaden Abbott's revenue and profit streams and augment its product pipeline. The recent decline in Abbott's share price has been steep and could deepen, but institutions that accumulated shares throughout 2025 are likely buyers at these discounted levels. Early technical support appears in the $105–$110 range, though it is not yet confirmed. The risk is that ABT could dip further to the low end of the target buy zone — potentially near $95 or lower — before a sustained rebound.
| 
